Regenicin Inc Stock OTC Bulletin Board

Regenicin, Inc. is a biotechnology company specializes in the development of regenerative cell therapies to restore the health of damaged tissues and organs. The Company is focused on developing and commercializing a lifesaving technology through the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures. Its product, NovaDerm, is a multi-layered tissue-engineered skin prepared by utilizing autologous skin cells. NovaDerm is a graftable cultured epithelium skin substitute containing both epidermal and dermal components. Its second product is TempaDerm. TempaDerm uses cells obtained from human donors to develop banks of cryo-preserved (frozen) cells and cultured skin substitutes to provide a continuous supply of non-allogenic skin substitutes to treat much smaller wound areas on patients, such as ulcers.